A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-02. Anything still debated is marked as such rather than presented as settled.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
The Journal of Psychiatric Research is a monthly peer-reviewed medical journal covering research in four major areas of psychiatry: clinical studies on normal and pathological human behavior; basic studies in psychiatry and related fields; clinical laboratory techniques such as neuroimaging, spectroscopy and other computer techniques used in research; advances in research methodology, including the clinical use of recent research findings. The journal was established in 1961 and is published by Elsevier. The current editor-in-chief is Eric Hollander (Albert Einstein College of Medicine). According to the Journal Citation Reports, the journal has a 2015 impact factor of 4.465.
Diphenoxylate (Lomotil, R-1132) is a centrally active opioid drug of the phenylpiperidine series that is used as a combination drug, prescribed in the United States under the trade name Lomotil, with atropine for the treatment of diarrhea. Diphenoxylate is an opioid and acts by slowing intestinal contractions; the atropine is present to prevent drug abuse and overdose. It should not be given to children due to the risk that they will stop breathing and should not be used in people with Clostridioides difficile infection.
The technology of this combined stimulation bioreactor could be used to grow bone cells more quickly and effectively in future clinical stem cell therapies. MC2 Biotek has also developed a bioreactor known as ProtoTissue that uses gas exchange to maintain high oxygen levels within the cell chamber; improving upon previous bioreactors, since the higher oxygen levels help the cell grow and undergo normal cell respiration. Active areas of research on bioreactors includes increasing production scale and refining the physiological environment, both of which could improve the efficiency and efficacy of bioreactors in research or clinical use. Bioreactors are currently used to study, among other things, cell and tissue level therapies, cell and tissue response to specific physiological environment changes, and development of disease and injury.
Sources: en.wikipedia.org
Ho's extensive research achievements have garnered news coverage in The Economist, Forbes, Nature, CNN, NPR, as well as The Washington Post. He was also featured in the National Geographic Channel program, Known Universe. Most recently, the Augmented AI platform was featured by FuturizeX, a partnership between the X PRIZE Foundation and UCLA. Recent clinical advances using this AI approach to enhance clinical outcomes were recognized among the finalists for the SLAS Innovation Award, selection among the SLAS Technology 10, and featured at the PM3 panel at InnovFest Unbound. Ho currently serves as the Director of The N.1 Institute for Health (N.1), which was previously known as SINAPSE, as well as Director of the Institute for Digital Medicine (WisDM) at the Yong Loo Lin School of Medicine, National University of Singapore. N.1 and WisDM are clinical stage research institutes that harnesses AI and Digital Medicine for novel clinical trial designs for interventional studies. Over ten first-in-human clinical studies based on N.1 and WisDM-developed technologies are ongoing or nearing clearance for the start of prospective clinical studies. N.1 and WisDM have pioneered the development and subsequent clinical translation of platforms pertaining to N-of-1 medicine, digital therapeutics, COVID-19 therapeutic regimen optimization, pain management, cognitive neuroengineering, and novel drug development, among many others. Ho is an elected member of the US National Academy of Inventors (NAI).
=== The catalytic protein === The main catalytic protein in telomerase is telomerase reverse transcriptase, 2627 amino acids long in humans. The protein consists of four conserved domains (RNA-Binding Domain (TRBD), fingers, palm and thumb), organized into a "right hand" ring configuration that shares common features with retroviral reverse transcriptases, viral RNA replicases and bacteriophage B-family DNA polymerases. TERT proteins from many eukaryotes have been sequenced.
== Description == N. christyi is a medium to moderately long, somewhat compressed, moderately slender-bodied, but heavily built snake, with a medium length tapering tail. The head is short, with an indistinct canthus, and is distinct from the neck. The neck is capable of being spread into a hood. The eyes are relatively small in size with round pupils. The dorsal scales are smooth and shiny. The average total length (including tail) of an adult specimen is around 1.1 metres (3.6 ft), but it may grow to upwards of 2.3 metres (7.5 ft) The rostral is once and a half as broad as deep, and is just visible from above. The internasals are as long as the prefrontals, and are extensively in contact with the preocular. The frontal is small, not longer than broad, broadest behind, forming very open angles in front and behind, not quite as long as its distance from the rostral, half as long as the parietals. The supraocular is much narrower than the frontal. The posterior nasal is in contact with the single preocular. There are two or three postoculars. The temporals are 2+2 or 2+3. There are seven upper labials, the third and fourth entering the eye, the fourth and fifth in contact with the lower postocular. There are four lower labials in contact with the anterior chin shields. The posterior chin shields are narrower and a little shorter than the anterior chin shields and separated by one scale. The dorsal scales are in 19 rows on the neck, and in 17 rows at midbody. The ventrals number 221. The anal is entire. The subcaudals number 70. Colouration is blackish brown above.
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.